AZN
February 8, 2024 - AI Summary
Undervalued by 10.5% based on the discounted cash flow analysis.
Market cap | $235.01 Billion |
---|---|
Enterprise Value | $261.54 Billion |
Dividend Yield | $1.436 (1.89%) |
Earnings per Share | $2.03 |
Beta | 0.54 |
Outstanding Shares | 3,100,442,576 |
Avg 30 Day Volume | 6,704,342 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 37.13 |
---|---|
PEG | 178.61 |
Price to Sales | 5.17 |
Price to Book Ratio | 6.47 |
Enterprise Value to Revenue | 5.49 |
Enterprise Value to EBIT | 34.87 |
Enterprise Value to Net Income | 41 |
Total Debt to Enterprise | 0.13 |
Debt to Equity | 0.92 |
No data
No data
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...